What a way to start 2025!!! I am extremely grateful to the commission that positively evaluated my application. But most of all, thanks thanks thanks to my mentor @prat-aleix-md.bsky.social for believing in me, sometimes even more than myself 😝

Oh, and happy new year from Sicily to you all

For sure, outstanding discussion by prof Harold Burstein from @dfcibreastonc.bsky.social. Here some of his conclusions (and the previous algorithm was his slides as well as the comparison in toxicities and mPFS)

Also, the toxicity profiles compared to other oral SERD was quite good. This positions the combo as the potential standard II-line for ALL patients progressing to CDK4/6i where the dependency on ER pathway is still there. BUT who are these pts? 👇🏻

BUT, differently from imlune alone, imlune+abema was also superior to imlune in ALL pts, including those without ESR1mut, and after previous I-line CDK4/6inhibitors (mostly palbo/ribo) and in PI3Kpathway-altered BC, with a mPFS that is superior to every ET-based regimen so far

My first takeaway from #SABCS24. The EMBER3 of new oral SERD imlunestrant vs fulvestrant or exemestane vs imlune+abemaciclib in HR+/HER2neg MBC. This study showed in II-line scenario that imlunestrant is superior to ET alone in ESR1mutant patients. AKA welcome to elacestrant 2 👇🏻

Barcelona!

Bluesy night before a very long trip to #SABCS24.

In addition, we found out that molecular downstaging or persistence of ROR-P-low or Luminal A subtype from baseline to surgery showed a trend for improved outcomes

We then observed that both NACT and NET promote a molecular downstaging inducing molecular subtype shifting to luminal A or normal-like and to ROR-P-low-risk class

We took into account 3 different response type, i.e. molecular responders (i.e. ROR-low and Ki67 10% after treatment) and pathologic responders. Using multiclass SAM, we revealed differential baseline gene expression differences among responders and non responders to NACT and NET

First, we compared NACT to NET in a clinical practice cohort of 186 patients, and confirmed that NACT is associated with higher rates of RCB-0/I than NET in stage I-IIIB HR+/HER2- BC. Both in the entire study cohort, then after propensity score matching to mitigate selection bias

Finally out in @ESMO_Open the main findings of my #ESMO #Fellowship research project focused on the
identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer.
What did we find? A thread 🧵

Ready for the #envisionsummit2024 from #SOLTI with great speakers diving deep into the future of prognostic/predictive biomarkers in #breastcancer and new treatment strategies

Ok let’s see how this app works. First post (taken from De Ashley Rubin, who I think is not on 🦋) very nice and helpful for researchers “lost in descriptionland”. I’ll use screenshots of her X thread.